Synthetic Biologics Inc (NYSE: SYN) Delivers Update on SYN-020 Intestinal Alkaline Phosphatase Stage 1 Single-Ascending Dosage Scientific Pilot

Synthetic Biologics Inc (NYSE: SYN) today announced that patient medicating and scrutiny has been accomplished in its Stage 1, exposed label, single-ascending dose (SAD) scientific pilot of SYN-020 intestinal alkaline phosphatase (IAP).

Stage 1 SAD study registered 24 fit grownup helpers

The Stage 1 SAD study registered 24 fit adult helpers into four units with SYN-020 given vocally as single amounts reaching from 5 mg to 150 mg daily. Examines of initial data established that SYN-020 upheld a good security outline, was well borne at all dosage levels, and no adversative events were accredited to the study drug. The study described no serious adverse effects.

“SYN-020 is an inspiring, versatile package that has the latent to become a multi-indication, platform. It is proficient of tackling a considerable unmet necessity for ground-breaking new cures targeting complaints stanching from gastrointestinal (GI) irritation,” said Steven A. Shallcross, Chief Executive Officer of Synthetic Biologics. “U.S. cases of celiac illness are projected to exceed 4.3 million by 2023, demonstrating a noteworthy market opening for a highly segregated product such as SYN-020. We are very heartened by these constructive Stage 1 outcomes and look forward to SYN-020’s continued growth, which embraces the premeditated beginning of a subsequent Stage 1, multiple-ascending dosage study during the third quarter of 2021.”

Second Stage 1 scientific trial to start in the third quarter of 2021

A second Stage 1 scientific is projected to begin during the third quarter of 2021.Topline consequences from this scientific trial are expected during the second quarter of 2022. Both Stage 1 SAD and MAD studies are envisioned to support the expansion of SYN-020 in manifold possible medical signs. These signs include celiac disease, nonalcoholic fatty liver disease (NAFLD), and signs to treat and stop metabolic and seditious illnesses related to getting old, reinforced by the company’s partnership with Massachusetts General Hospital.

Leave a Comment

Your email address will not be published.